CAL02 + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumonia, Bacterial
Conditions
Pneumonia, Bacterial
Trial Timeline
Jul 22, 2023 → Sep 7, 2026
NCT ID
NCT05776004About CAL02 + Placebo
CAL02 + Placebo is a phase 2 stage product being developed by Eagle Pharmaceuticals for Pneumonia, Bacterial. The current trial status is active. This product is registered under clinical trial identifier NCT05776004. Target conditions include Pneumonia, Bacterial.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05776004 | Phase 2 | Active |
Competing Products
20 competing products in Pneumonia, Bacterial
Other Products from Eagle Pharmaceuticals
Arm 1 Cataract Surgery performed with remimazolam as sedative + Arm 2 Cataract Surgery performed with standard of care sedativeApproved
77
Placebo + Mesalamine + MesalaminePhase 3
69
Ryanodex and Standard of CarePhase 3
69
Ryanodex (dantrolene sodium) for injectable suspensionPhase 2
44
Dantrolene sodium for injectable suspensionPhase 2
44